查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1610033

去势抗性前列腺癌市场规模、份额和趋势分析报告：按治疗方法、地区和细分市场预测，2025-2030

Castrate-resistant Prostate Cancer Market Size, Share & Trends Analysis Report By Therapy (Chemotherapy, Hormonal Therapy, Immunotherapy, Radiotherapy), By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 90 Pages | 商品交期: 2-10个工作天内

价格

去势抗性前列腺癌市场成长与趋势

预计到2030年，全球去势抗性前列腺癌（CRPC）市场规模将达214.4亿美元，预计2025年至2030年复合年增长率为8.7%。这一增长是由全球去势抗性前列腺癌和不健康生活方式日益增加的负担所推动的。

此外，预计新产品的推出和人们对前列腺癌的认识不断提高，预计也将在预测期内提高市场成长率。此外，新药采用的增加和强大的管道可能是预测期内加速市场成长的因素。

由于先进荷尔蒙疗法在 CRPC 管理中的有效性，荷尔蒙疗法细分市场在全球去势抗性前列腺癌市场中占据主导地位，到 2024 年，其销售份额将达到 42.2%。此细分市场的推动因素是 Xtandi（Enzalutamide）市场渗透率的不断提高以及 Erleada（阿帕鲁胺）在美国、欧洲和日本的推出。此外，Xtandi 其他适应症的开发和核准正在推动该领域的成长。由于计划在预测期内推出的强大管道药物的存在，预计免疫疗法也将成为成长最快的领域。

北美的压倒性份额是由于高疾病负担、技术进步、积极的政府政策、消费者对该疾病的认识提高以及医疗基础设施的改善。该地区主要企业的存在也是推动该地区市场成长的重要因素。此外，印度和中国等新兴国家的疾病盛行率很高，导致对改进治疗的需求增加、医疗保健成本增加以及政府对肿瘤学和其他研究活动的资助增加。因此，这些因素预计将在预测期内推动亚太市场的发展。

该市场拥有赛诺菲、强生服务公司、辉瑞公司、安斯泰来製药公司和拜耳公司等主要企业，因此难以满足高资本要求，并为新进入者创造了机会。主要参与企业正在大力投资开发新药，以维持其市场地位并获得市场占有率。

去势抗性前列腺癌市场报告亮点

  • 由于先进荷尔蒙疗法在 CRPC 管理中的有效性，荷尔蒙疗法细分市场在全球去势抗性前列腺癌市场中占据主导地位，到 2024 年，其销售份额将达到 42.2%。
  • 由于人们越来越认识到免疫疗法在 CRPC 患者中提供持久反应和提高整体存活率的潜力，预计从 2025 年到 2030 年，免疫疗法领域的复合年增长率将达到 11.9%。
  • 2024年全球去势抗性前列腺癌市场中，北美将占最大的销售份额，达到47.9%。
  • 由于中国、日本和印度等人口稠密国家的前列腺癌盛行率不断上升，预计亚太地区去势抗性前列腺癌市场将在预测期内增长最快。

目录

第一章调查方法和范围

第 2 章执行摘要

第 3 章去势抗性前列腺癌市场变数、趋势与范围

  • 市场体系展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 营商环境分析
    • 产业分析-波特五力分析
    • PESTLE分析

第四章去势抗性前列腺癌市场：治疗方法业务分析

  • 2024年及2030年治疗市场占有率
  • 治疗方法细分仪表板
  • 2018-2030 年市场规模、预测与趋势分析（按治疗方法）
  • 化疗
  • 荷尔蒙疗法
  • 免疫疗法
  • 放射治疗

第五章去势抗性前列腺癌市场：治疗方法、地区、估计和趋势分析

  • 2024 年及 2030 年按地区分類的市场占有率分析
  • 区域市场仪表板
  • 2018-2030年市场规模、预测趋势分析
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麦
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 泰国
    • 韩国
    • 澳洲
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东/非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第六章 竞争状况

  • 参与者概览
  • 公司市场分析
  • 公司分类
  • 策略规划
  • 公司简介/上市公司
    • Sanofi
    • Johnson & Johnson Services, Inc.
    • Pfizer, Inc.
    • Astellas Pharma, Inc.
    • Bayer AG
Product Code: GVR-4-68039-237-3

Castrate-resistant Prostate Cancer Market Growth & Trends:

The global castrate-resistant prostate cancer market size is expected to reach USD 21.44 billion in 2030 and is projected to grow at a CAGR of 8.7% from 2025 to 2030. This growth is driven by the rising global burden of castrate-resistant prostate cancer and unhealthy lifestyle.

In addition, the anticipated launch of new products and rising awareness of prostate cancer are likely to enhance the growth rate of the market over the forecast period. Moreover, the growing adoption of novel drugs and strong pipeline are factors likely to accelerate market growth during the forecast period.

The hormonal therapy segment dominated the global castrate-resistant prostate cancer market with a revenue share of 42.2% in 2024 due to the effectiveness of advanced hormonal therapies in managing CRPC. The segment is driven by increasing market penetration of Xtandi (enzalutamide) and the launch of Erleada (apalutamide) in the U.S., Europe, and Japan. Furthermore, the development and approval of an additional indication of Xtandi are driving the segment growth. In addition, immunotherapy is estimated to be the fastest-growing segment due to the presence of strong product pipeline drugs, which are projected to be launched during the forecast period.

North America's dominant share is attributable to high disease burden, technological advancements, proactive government measures, increased consumer awareness about the disease, and improvements in healthcare infrastructure. The presence of key players in this region is a key factor in boosting the growth of the market in the region. In addition, developing countries such as India and China are witnessing a high incidence of the disease that has resulted in an increase in the demand for improved therapeutics, an increase in healthcare expenditure, and a rise in government funding for oncology and other research activities. Thus, these factors are expected to drive the market in the Asia Pacific during the forecast period.

The presence of prominent players such as Sanofi; Johnson and Johnson Services, Inc.; Pfizer, Inc.; Astellas Pharma, Inc.; and Bayer AG in this market space significantly diminishes the opportunities of a new entry as it is difficult to match the high capital requirements. Key players are investing highly in the development of new molecules to maintain their presence in the market and acquire market share.

Castrate-resistant Prostate Cancer Market Report Highlights:

  • The hormonal therapy segment dominated the global castrate-resistant prostate cancer market with a revenue share of 42.2% in 2024 due to the effectiveness of advanced hormonal therapies in managing CRPC.
  • The immunotherapy segment is projected to grow at a CAGR of 11.9% from 2025 to 2030, driven by the increasing recognition of immunotherapy's potential to provide durable responses and improve overall survival in CRPC patients
  • North America held the largest revenue share of 47.9% of the global castrate-resistant prostate cancer market in 2024
  • Asia Pacific castrate-resistant prostate cancer market is anticipated to grow fastest throughout the forecast period, driven by the increasing prevalence of prostate cancer in densely populated countries such as China, Japan, and India

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Therapy
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Castrate-resistant Prostate Cancer Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTLE Analysis

Chapter 4. Castrate-resistant Prostate Cancer Market: Therapy Business Analysis

  • 4.1. Therapy Market Share, 2024 & 2030
  • 4.2. Therapy Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Therapy, 2018 to 2030 (USD Million)
  • 4.4. Chemotherapy
    • 4.4.1. Chemotherapy market, 2018 - 2030 (USD Million)
  • 4.5. Hormonal Therapy
    • 4.5.1. Hormonal Therapy market, 2018 - 2030 (USD Million)
  • 4.6. Immunotherapy
    • 4.6.1. Immunotherapy market, 2018 - 2030 (USD Million)
  • 4.7. Radiotherapy
    • 4.7.1. Radiotherapy market, 2018 - 2030 (USD Million)

Chapter 5. Castrate-resistant Prostate Cancer Market: Region Estimates & Trend Analysis by Therapy

  • 5.1. Region Market Share Analysis, 2024 & 2030
  • 5.2. Region Market Dashboard
  • 5.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 5.4. North America
    • 5.4.1. North America castrate-resistant prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.4.2. U.S.
      • 5.4.2.1. Key country dynamics
      • 5.4.2.2. Regulatory framework
      • 5.4.2.3. Competitive insights
      • 5.4.2.4. U.S. castrate-resistant prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.4.3. Canada
      • 5.4.3.1. Key country dynamics
      • 5.4.3.2. Regulatory framework
      • 5.4.3.3. Competitive insights
      • 5.4.3.4. Canada castrate-resistant prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.4.4. Mexico
      • 5.4.4.1. Key country dynamics
      • 5.4.4.2. Regulatory framework
      • 5.4.4.3. Competitive insights
      • 5.4.4.4. Mexico castrate-resistant prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.5. Europe
    • 5.5.1. Europe castrate-resistant prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.5.2. UK
      • 5.5.2.1. Key country dynamics
      • 5.5.2.2. Regulatory framework
      • 5.5.2.3. Competitive insights
      • 5.5.2.4. UK castrate-resistant prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.5.3. Germany
      • 5.5.3.1. Key country dynamics
      • 5.5.3.2. Regulatory framework
      • 5.5.3.3. Competitive insights
      • 5.5.3.4. Germany castrate-resistant prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.5.4. France
      • 5.5.4.1. Key country dynamics
      • 5.5.4.2. Regulatory framework
      • 5.5.4.3. Competitive insights
      • 5.5.4.4. France castrate-resistant prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.5.5. Italy
      • 5.5.5.1. Key country dynamics
      • 5.5.5.2. Regulatory framework
      • 5.5.5.3. Competitive insights
      • 5.5.5.4. Italy castrate-resistant prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.5.6. Spain
      • 5.5.6.1. Key country dynamics
      • 5.5.6.2. Regulatory framework
      • 5.5.6.3. Competitive insights
      • 5.5.6.4. Spain castrate-resistant prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.5.7. Norway
      • 5.5.7.1. Key country dynamics
      • 5.5.7.2. Regulatory framework
      • 5.5.7.3. Competitive insights
      • 5.5.7.4. Norway castrate-resistant prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.5.8. Sweden
      • 5.5.8.1. Key country dynamics
      • 5.5.8.2. Regulatory framework
      • 5.5.8.3. Competitive insights
      • 5.5.8.4. Sweden castrate-resistant prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.5.9. Denmark
      • 5.5.9.1. Key country dynamics
      • 5.5.9.2. Regulatory framework
      • 5.5.9.3. Competitive insights
      • 5.5.9.4. Denmark castrate-resistant prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.6. Asia Pacific
    • 5.6.1. Asia Pacific castrate-resistant prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.6.2. Japan
      • 5.6.2.1. Key country dynamics
      • 5.6.2.2. Regulatory framework
      • 5.6.2.3. Competitive insights
      • 5.6.2.4. Japan castrate-resistant prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.6.3. China
      • 5.6.3.1. Key country dynamics
      • 5.6.3.2. Regulatory framework
      • 5.6.3.3. Competitive insights
      • 5.6.3.4. China castrate-resistant prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.6.4. India
      • 5.6.4.1. Key country dynamics
      • 5.6.4.2. Regulatory framework
      • 5.6.4.3. Competitive insights
      • 5.6.4.4. India castrate-resistant prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.6.5. Thailand
      • 5.6.5.1. Key country dynamics
      • 5.6.5.2. Regulatory framework
      • 5.6.5.3. Competitive insights
      • 5.6.5.4. Thailand castrate-resistant prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.6.6. South Korea
      • 5.6.6.1. Key country dynamics
      • 5.6.6.2. Regulatory framework
      • 5.6.6.3. Competitive insights
      • 5.6.6.4. South Korea castrate-resistant prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.6.7. Australia
      • 5.6.7.1. Key country dynamics
      • 5.6.7.2. Regulatory framework
      • 5.6.7.3. Competitive insights
      • 5.6.7.4. Australia castrate-resistant prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.7. Latin America
    • 5.7.1. Latin America castrate-resistant prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.7.2. Brazil
      • 5.7.2.1. Key country dynamics
      • 5.7.2.2. Regulatory framework
      • 5.7.2.3. Competitive insights
      • 5.7.2.4. Brazil castrate-resistant prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.7.3. Argentina
      • 5.7.3.1. Key country dynamics
      • 5.7.3.2. Regulatory framework
      • 5.7.3.3. Competitive insights
      • 5.7.3.4. Argentina castrate-resistant prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.8. Middle East & Africa
    • 5.8.1. Middle East & Africa castrate-resistant prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.8.2. South Africa
      • 5.8.2.1. Key country dynamics
      • 5.8.2.2. Regulatory framework
      • 5.8.2.3. Competitive insights
      • 5.8.2.4. South Africa castrate-resistant prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.8.3. Saudi Arabia
      • 5.8.3.1. Key country dynamics
      • 5.8.3.2. Regulatory framework
      • 5.8.3.3. Competitive insights
      • 5.8.3.4. Saudi Arabia castrate-resistant prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.8.4. UAE
      • 5.8.4.1. Key country dynamics
      • 5.8.4.2. Regulatory framework
      • 5.8.4.3. Competitive insights
      • 5.8.4.4. UAE castrate-resistant prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.8.5. Kuwait
      • 5.8.5.1. Key country dynamics
      • 5.8.5.2. Regulatory framework
      • 5.8.5.3. Competitive insights
      • 5.8.5.4. Kuwait castrate-resistant prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 6. Competitive Landscape

  • 6.1. Participant Overview
  • 6.2. Company Market Position Analysis
  • 6.3. Company Categorization
  • 6.4. Strategy Mapping
  • 6.5. Company Profiles/Listing
    • 6.5.1. Sanofi
      • 6.5.1.1. Overview
      • 6.5.1.2. Financial performance
      • 6.5.1.3. Material benchmarking
      • 6.5.1.4. Strategic initiatives
    • 6.5.2. Johnson & Johnson Services, Inc.
      • 6.5.2.1. Overview
      • 6.5.2.2. Financial performance
      • 6.5.2.3. Material benchmarking
      • 6.5.2.4. Strategic initiatives
    • 6.5.3. Pfizer, Inc.
      • 6.5.3.1. Overview
      • 6.5.3.2. Financial performance
      • 6.5.3.3. Material benchmarking
      • 6.5.3.4. Strategic initiatives
    • 6.5.4. Astellas Pharma, Inc.
      • 6.5.4.1. Overview
      • 6.5.4.2. Financial performance
      • 6.5.4.3. Material benchmarking
      • 6.5.4.4. Strategic initiatives
    • 6.5.5. Bayer AG
      • 6.5.5.1. Overview
      • 6.5.5.2. Financial performance
      • 6.5.5.3. Material benchmarking
      • 6.5.5.4. Strategic initiatives

List of Tables

  • Table 1. List of secondary sources
  • Table 2. List of abbreviations
  • Table 3. Castrate-resistant prostate cancer market, by therapy, 2018 - 2030 (USD Million)
  • Table 4. Castrate-resistant prostate cancer market, by region, 2018 - 2030 (USD Million)
  • Table 5. North America castrate-resistant prostate cancer market, by country, 2018 - 2030 (USD Million)
  • Table 6. North America castrate-resistant prostate cancer market, by therapy, 2018 - 2030 (USD Million)
  • Table 7. U.S. castrate-resistant prostate cancer market, by therapy, 2018 - 2030 (USD Million)
  • Table 8. Canada castrate-resistant prostate cancer market, by therapy, 2018 - 2030 (USD Million)
  • Table 9. Mexico castrate-resistant prostate cancer market, by therapy, 2018 - 2030 (USD Million)
  • Table 10. Europe castrate-resistant prostate cancer market, by country, 2018 - 2030 (USD Million)
  • Table 11. Europe castrate-resistant prostate cancer market, by therapy, 2018 - 2030 (USD Million)
  • Table 12. UK castrate-resistant prostate cancer market, by therapy, 2018 - 2030 (USD Million)
  • Table 13. Germany castrate-resistant prostate cancer market, by therapy, 2018 - 2030 (USD Million)
  • Table 14. France castrate-resistant prostate cancer market, by therapy, 2018 - 2030 (USD Million)
  • Table 15. Italy castrate-resistant prostate cancer market, by therapy, 2018 - 2030 (USD Million)
  • Table 16. Spain castrate-resistant prostate cancer market, by therapy, 2018 - 2030 (USD Million)
  • Table 17. Norway castrate-resistant prostate cancer market, by therapy, 2018 - 2030 (USD Million)
  • Table 18. Sweden castrate-resistant prostate cancer market, by therapy, 2018 - 2030 (USD Million)
  • Table 19. Denmark castrate-resistant prostate cancer market, by therapy, 2018 - 2030 (USD Million)
  • Table 20. Asia Pacific castrate-resistant prostate cancer market, by country, 2018 - 2030 (USD Million)
  • Table 21. Asia Pacific castrate-resistant prostate cancer market, by therapy, 2018 - 2030 (USD Million)
  • Table 22. China castrate-resistant prostate cancer market, by therapy, 2018 - 2030 (USD Million)
  • Table 23. Japan castrate-resistant prostate cancer market, by therapy, 2018 - 2030 (USD Million)
  • Table 24. India castrate-resistant prostate cancer market, by therapy, 2018 - 2030 (USD Million)
  • Table 25. Thailand castrate-resistant prostate cancer market, by therapy, 2018 - 2030 (USD Million)
  • Table 26. South Korea castrate-resistant prostate cancer market, by therapy, 2018 - 2030 (USD Million)
  • Table 27. Australia castrate-resistant prostate cancer market, by therapy, 2018 - 2030 (USD Million)
  • Table 28. Latin America castrate-resistant prostate cancer market, by country, 2018 - 2030 (USD Million)
  • Table 29. Latin America crowns and bridges market, by therapy, 2018 - 2030 (USD Million)
  • Table 30. Brazil castrate-resistant prostate cancer market, by therapy, 2018 - 2030 (USD Million)
  • Table 31. Agrnetina castrate-resistant prostate cancer market, by therapy, 2018 - 2030 (USD Million)
  • Table 32. Middle East & Africa castrate-resistant prostate cancer market, by country, 2018 - 2030 (USD Million)
  • Table 33. Middle East & Africa crowns and bridges market, by therapy, 2018 - 2030 (USD Million)
  • Table 34. South Africa castrate-resistant prostate cancer market, by therapy, 2018 - 2030 (USD Million)
  • Table 35. Saudi Arabia castrate-resistant prostate cancer market, by therapy, 2018 - 2030 (USD Million)
  • Table 36. UAE castrate-resistant prostate cancer market, by therapy, 2018 - 2030 (USD Million)
  • Table 37. Kuwait castrate-resistant prostate cancer market, by therapy, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Castrate-resistant prostate cancer market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Competitive landscape
  • Fig. 10 Castrate-resistant prostate cancer market dynamics
  • Fig. 11 Castrate-resistant prostate cancer market: Porter's five forces analysis
  • Fig. 12 Castrate-resistant prostate cancer market: PESTLE analysis
  • Fig. 13 Castrate-resistant prostate cancer market: Therapy segment dashboard
  • Fig. 14 Castrate-resistant prostate cancer market: Therapy market share analysis, 2024 & 2030
  • Fig. 15 Chemotherapy market, 2018 - 2030 (USD Million)
  • Fig. 16 Hormonal Therapy market, 2018 - 2030 (USD Million)
  • Fig. 17 Immunotherapy market, 2018 - 2030 (USD Million)
  • Fig. 18 Radiotherapy market, 2018 - 2030 (USD Million)
  • Fig. 19 Castrate-resistant prostate cancer market revenue, by region
  • Fig. 20 Region marketplace: Key takeaways
  • Fig. 21 North America region dynamics
  • Fig. 22 North America castrate-resistant prostate cancer market, 2018 - 2030 (USD Million)
  • Fig. 23 U.S. country dynamics
  • Fig. 24 U.S. castrate-resistant prostate cancer market, 2018 - 2030 (USD Million)
  • Fig. 25 Canada country dynamics
  • Fig. 26 Canada castrate-resistant prostate cancer market, 2018 - 2030 (USD Million)
  • Fig. 27 Mexico country dynamics
  • Fig. 28 Mexico castrate-resistant prostate cancer market, 2018 - 2030 (USD Million)
  • Fig. 29 Europe region dynamics
  • Fig. 30 Europe castrate-resistant prostate cancer market, 2018 - 2030 (USD Million)
  • Fig. 31 UK country dynamics
  • Fig. 32 UK castrate-resistant prostate cancer market, 2018 - 2030 (USD Million)
  • Fig. 33 Germany country dynamics
  • Fig. 34 Germany castrate-resistant prostate cancer market, 2018 - 2030 (USD Million)
  • Fig. 35 France country dynamics
  • Fig. 36 France castrate-resistant prostate cancer market, 2018 - 2030 (USD Million)
  • Fig. 37 Italy country dynamics
  • Fig. 38 Italy castrate-resistant prostate cancer market, 2018 - 2030 (USD Million)
  • Fig. 39 Spain country dynamics
  • Fig. 40 Spain castrate-resistant prostate cancer market, 2018 - 2030 (USD Million)
  • Fig. 41 Norway country dynamics
  • Fig. 42 Norway castrate-resistant prostate cancer market, 2018 - 2030 (USD Million)
  • Fig. 43 Sweden country dynamics
  • Fig. 44 Sweden castrate-resistant prostate cancer market, 2018 - 2030 (USD Million)
  • Fig. 45 Denmark country dynamics
  • Fig. 46 Denmark castrate-resistant prostate cancer market, 2018 - 2030 (USD Million)
  • Fig. 47 Asia Pacific region dynamics

  • Fig. 48 Asia Pacific castrate-resistant prostate cancer market, 2018 - 2030 (USD Million)
  • Fig. 49 China country dynamics
    • Fig. 50 China castrate-resistant prostate cancer market, 2018 - 2030 (USD Million)
  • Fig. 51 Japan country dynamics
  • Fig. 52 Japan castrate-resistant prostate cancer market, 2018 - 2030 (USD Million)
  • Fig. 53 China country dynamics
  • Fig. 54 China castrate-resistant prostate cancer market, 2018 - 2030 (USD Million)
  • Fig. 55 India country dynamics
  • Fig. 56 India castrate-resistant prostate cancer market, 2018 - 2030 (USD Million)
  • Fig. 57 Thailand country dynamics
  • Fig. 58 Thailand castrate-resistant prostate cancer market, 2018 - 2030 (USD Million)
  • Fig. 59 South Korea country dynamics
  • Fig. 60 South Korea castrate-resistant prostate cancer market, 2018 - 2030 (USD Million)
  • Fig. 61 Australia country dynamics
  • Fig. 62 Australia castrate-resistant prostate cancer market, 2018 - 2030 (USD Million)
  • Fig. 63 Latin America region dynamics
  • Fig. 64 Latin America castrate-resistant prostate cancer market, 2018 - 2030 (USD Million)
  • Fig. 65 Brazil country dynamics
  • Fig. 66 Brazil castrate-resistant prostate cancer market, 2018 - 2030 (USD Million)
  • Fig. 67 Argentina country dynamics
  • Fig. 68 Argentina castrate-resistant prostate cancer market, 2018 - 2030 (USD Million)
  • Fig. 69 Middle East & Africa region dynamics
  • Fig. 70 Middle East & Africa castrate-resistant prostate cancer market, 2018 - 2030 (USD Million)
  • Fig. 71 South Africa country dynamics
  • Fig. 72 South Africa castrate-resistant prostate cancer market, 2018 - 2030 (USD Million)
  • Fig. 73 Saudi Arabia country dynamics
  • Fig. 74 Saudi Arabia castrate-resistant prostate cancer market, 2018 - 2030 (USD Million)
  • Fig. 75 UAE country dynamics
  • Fig. 76 UAE castrate-resistant prostate cancer market, 2018 - 2030 (USD Million)
  • Fig. 77 Kuwait country dynamics
  • Fig. 78 Kuwait castrate-resistant prostate cancer market, 2018 - 2030 (USD Million
  • Fig. 79 Company categorization
  • Fig. 80 Company market position analysis
  • Fig. 81 Strategic framework